Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Developing First-in-Class Ligands for RFWD3, Utilizing a Novel Virtual Screening Method
FY 2022-23
Summary
Previously published unbiased genetic screens have revealed that the Ring Finger And WD Repeat Domain 3 (RFWD3) protein is driving resistance to frontline anticancer treatments such as cisplatin and ultraviolet light. To validate RFWD3 as a target for anticancer therapy, further studies are required to understand its biology and chemistry. A key tool required to conduct these studies is a chemical probe: a potent and selective drug-like molecule that can be used to turn off RFWD3 in cancer cells.
My goal is to identify and validate the first lead molecules towards a chemical probe for RFWD3, which will enable further exploration of this promising therapeutic target. A novel hybrid virtual screening method, using a combination of state-of-the-art informatics tools, will be applied to identify the best chemical probe candidates for RFWD3 out of billions of commercially available molecules. These candidates will then be tested experimentally to determine how efficiently they engage RFWD3.
The successful development of a robust chemical probe for RFWD3 will allow a better understanding of its role in cancer, opening the possibility of targeting this protein in combination with chemotherapeutic agents for cancer patients. The novel computational approach that I will employ will also demonstrate an efficient strategy to screen ultra-large chemical libraries in silico. This will contribute to the development of novel technologies necessary to achieve the ambitious goal of Target 2035, which is to discover chemical probes for all human proteins by the year 2035.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486447
Name
Kwak Hae Jin (Angela)
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing First-in-Class Ligands for RFWD3, Utilizing a Novel Virtual Screening Method
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biophysics; Combination Therapy For Cancer; Ligand Design; Virtual Screening
Abstract
Previously published unbiased genetic screens have revealed that the Ring Finger And WD Repeat Domain 3 (RFWD3) protein is driving resistance to frontline anticancer treatments such as cisplatin and ultraviolet light. To validate RFWD3 as a target for anticancer therapy, further studies are required to understand its biology and chemistry. A key tool required to conduct these studies is a chemical probe: a potent and selective drug-like molecule that can be used to turn off RFWD3 in cancer cells.
My goal is to identify and validate the first lead molecules towards a chemical probe for RFWD3, which will enable further exploration of this promising therapeutic target. A novel hybrid virtual screening method, using a combination of state-of-the-art informatics tools, will be applied to identify the best chemical probe candidates for RFWD3 out of billions of commercially available molecules. These candidates will then be tested experimentally to determine how efficiently they engage RFWD3.
The successful development of a robust chemical probe for RFWD3 will allow a better understanding of its role in cancer, opening the possibility of targeting this protein in combination with chemotherapeutic agents for cancer patients. The novel computational approach that I will employ will also demonstrate an efficient strategy to screen ultra-large chemical libraries in silico. This will contribute to the development of novel technologies necessary to achieve the ambitious goal of Target 2035, which is to discover chemical probes for all human proteins by the year 2035.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kwak, Hae Jin (Angela)
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~